Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Cited In for PubMed (Select 17413693)

1.

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53.

PMID:
26322666
2.

Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003-2014.

Huang P, Tan J, Ma W, Zheng H, Lu Y, Wang N, Peng Z, Yu R.

BMJ Open. 2015 May 22;5(5):e007508. doi: 10.1136/bmjopen-2014-007508.

3.

Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.

Bayoumi AM, Barnett PG, Joyce VR, Griffin SC, Sun H, Bansback NJ, Holodniy M, Sanders G, Brown ST, Kyriakides TC, Angus B, Cameron DW, Anis AH, Sculpher M, Owens DK.

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):382-91. doi: 10.1097/QAI.0000000000000002.

4.

Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China.

Liao L, Xing H, Su B, Wang Z, Ruan Y, Wang X, Liu Z, Lu Y, Yang S, Zhao Q, Vermund SH, Chen RY, Shao Y.

AIDS. 2013 Jul 17;27(11):1815-24. doi: 10.1097/QAD.0b013e3283611931.

5.

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.

Scherrer AU, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (SHCS).

PLoS One. 2012;7(11):e50307. doi: 10.1371/journal.pone.0050307. Epub 2012 Nov 26. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/78eea40b-1982-4734-b32e-f94ec6d7b85a.

6.

Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth.

Wong FL, Hsu AJ, Pham PA, Siberry GK, Hutton N, Agwu AL.

Pediatr Infect Dis J. 2012 Dec;31(12):1279-83. doi: 10.1097/INF.0b013e31826fd3e7.

7.

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina JM, de Truchis P.

PLoS One. 2012;7(5):e36673. doi: 10.1371/journal.pone.0036673. Epub 2012 May 10.

8.

Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.

Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, Orrell C, Zeinecker J, Sanne I, Wood R, McIntyre J, Stevens W; CIPRA-SA project 1 study team.

Antivir Ther. 2012;17(2):313-20. doi: 10.3851/IMP1985. Epub 2011 Nov 18.

9.

Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings.

Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé JL, Dieng-Sarr A, Agbaji O, Onwujekwe DI, Gashau W, Nkado R, Ekong E, Okonkwo P, Murphy RL, Kanki PJ; APIN PEPFAR Team.

Clin Infect Dis. 2011 Dec;53(12):1283-90. doi: 10.1093/cid/cir729.

10.

Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.

El-Khatib Z, Delong AK, Katzenstein D, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Petzold M, Morris L, Kantor R.

J AIDS Clin Res. 2011 Feb 18;2(117). pii: 1000117.

11.

Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region.

Pujari S, Srasuebkul P, Sungkanuparph S, Lim PL, Kumarasamy N, Chuah J, Kumar RN, Chen YM, Oka S, Choi JY, Lee MP, Phanuphak P, Kamarulzaman A, Lee C, Fujie Z, Ditangco R, Saphonn V, Sirisanthana T, Merati TP, Smith J, Law MG.

J Antivir Antiretrovir. 2009 Nov 1;1(1):28-35.

12.

Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).

Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J, Sirisanthana T, Chen YM, Pujari S, Kumarasamy N, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang FJ, Mean CV, Merati T, Tau G, Smith J, Li PC; TREAT Asia HIV Observational Database.

HIV Med. 2010 Sep;11(8):519-29. doi: 10.1111/j.1468-1293.2010.00822.x. Epub 2010 Mar 21.

13.

Pediatric HIV clinical care resources and management practices in Asia: a regional survey of the TREAT Asia pediatric network.

Prasitsuebsai W, Bowen AC, Pang J, Hesp C, Kariminia A, Sohn AH; TREAT Asia Pediatric Program.

AIDS Patient Care STDS. 2010 Feb;24(2):127-31. doi: 10.1089/apc.2009.0224.

14.

Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China.

Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, Dou Z, Chiliade P, Wei X, Zhang F.

Clin Infect Dis. 2010 Jan 15;50(2):264-71. doi: 10.1086/649215.

15.

Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.

Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, Matee MI, Gundersen SG, Bruun JN.

BMC Infect Dis. 2009 Jul 7;9:108. doi: 10.1186/1471-2334-9-108.

16.

Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.

Reynolds SJ, Kityo C, Mbamanya F, Dewar R, Ssali F, Quinn TC, Mugyenyi P, Dybul M.

Antivir Ther. 2009;14(2):293-7.

17.

Increased mutations in Env and Pol suggest greater HIV-1 replication in sputum-derived viruses compared with blood-derived viruses.

Wagner TA, Tobin NH, McKernan JL, Xu M, Melvin AJ, Mohan KM, Learn GH, Mullins JI, Frenkel LM.

AIDS. 2009 May 15;23(8):923-8. doi: 10.1097/QAD.0b013e328329f964.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk